check_circleStudy Completed
Clinical Pharmacology
Bayer Identifier:
18359
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
EU CT Number:
Not Available
BAY59-7939, comparison of PK of Rivaroxaban and Apixaban
Trial purpose
To assess the plasma pharmacokinetics (PK) of
rivaroxaban and apixaban after multiple dosing and after
discontinuation of both.
rivaroxaban and apixaban after multiple dosing and after
discontinuation of both.
Key Participants Requirements
Sex
MaleAge
18 - 55 YearsTrial summary
Enrollment Goal
N/ATrial Dates
September 2015 - February 2016Phase
Phase 1Could I Receive a placebo
N/AProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
YesWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Mönchengladbach, 41061, Germany |
Trial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A